Coda Biotherapeutics Raises $28M in Financing
- Coda Biotherapeutics, a San Francisco CA-based preclinical-stage biopharmaceutical company, raised $28M in funding
- The round was led by Pacira BioSciences, Inc. with participation from MPM Capital, Versant Ventures and Silicon Valley Bank (SVB)
- As part of the financing, David Stack, chairman and CEO of Pacira Biosciences, has joined CODA’s board of directors
- The company intends to use the funds to expand operations and its business reach
- Coda is a preclinical-stage biopharmaceutical company that leverages a gene therapy approach to deploy a chemogenetic strategy for treating neurological disorders
- Coda expects this treatment will produce substantially improved and durable results while potentially avoiding off-target/adverse effects of currently available treatments
